Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of mRNA-1010 Seasonal Influenza Vaccine
NCT04956575Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Jul 2021
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mRNA-1010 in seasonal influenza (12 arms), sponsored by Moderna Inc. Primary endpoints: Solicited Local and Systemic Adverse Reactions at 7 days, Unsolicited Adverse Events at 28 days and 4 more. Started Jul 2021; status: completed.
02
Drugs
mRNA-1010
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT04956575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956575.